Harman Malhi, Leah J Homad, Yu-Hsin Wan, Bibhav Poudel, Brooke Fiala, Andrew J Borst, Jing Yang Wang, Carl Walkey, Jason Price, Abigail Wall, Suruchi Singh, Zoe Moodie, Lauren Carter, Simran Handa, Colin E Correnti, Barry L Stoddard, David Veesler, Marie Pancera, James Olson, Neil P King, Andrew T McGuire
Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths annually. EBV is also the etiological agent of infectious mononucleosis and is linked to multiple sclerosis and rheumatoid arthritis. Thus, an EBV vaccine would have a significant global health impact. EBV is orally transmitted and has tropism for epithelial and B cells. Therefore, a vaccine would need to prevent infection of both in the oral cavity. Passive transfer of monoclonal antibodies against the gH/gL glycoprotein complex prevent experimental EBV infection in humanized mice and rhesus macaques, suggesting that gH/gL is an attractive vaccine candidate...
June 21, 2022: Cell reports medicine